VEEVBULLISH

Gross Margin

75.0%

Higher than 71% of Healthcare sector peers

Updated 22h ago

Sector Performance

71th percentile

VEEV

75.0%

Sector Median

68.9%

Sector Avg

-20.2%

📊

Deep Analysis

Gross margin, the percentage of revenue remaining after deducting the cost of goods sold, stands at 75.0% for Veeva Systems.

This is above the healthcare sector median of 68.9%, placing the company in the 71st percentile among sector peers. The metric has been stable over the last eight quarters, with the most recent quarter-over-quarter change being +0.4% and no year-over-year change available. A high gross margin combined with a stable trend indicates consistent pricing power and cost control, reducing risk for investors. This performance directly supports the overall BULLISH verdict on the stock, as it reflects a durable competitive advantage.

Frequently Asked Questions

What does the Gross Margin tell investors about VEEV?

Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.

How is the Gross Margin calculated?

Gross Margin is calculated as: Gross Profit / Revenue.

How does VEEV's Gross Margin compare to its sector?

VEEV's Gross Margin of 75.0% compares to a Healthcare sector median of 68.9%, placing it in the 71th percentile.

Who are VEEV's closest peers by Gross Margin?

The closest Healthcare peers by Gross Margin include: AMGN (68.2%), TDOC (67.8%), TECH (66.9%), NTRA (64.8%), RMD (62.2%).

The Formula

Gross Profit / Revenue

Why It Matters

Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.

Master VEEV's Valuation

Get the complete institutional research report covering all fundamental and technical metrics.

View full VEEV research report

Free account — no credit card

VEEV

75.0%

Sector Median

68.9%

Sector Avg

-20.2%

How VEEV's Gross Margin compares to sector peers.

Not financial advice. Research tool only. Data may be delayed.